CFTR and urea cycle disorder: FDA-approved for the treatment of urea cycle disorders in children [73], 4-PBA has shown promise in reducing ER retention, preventing misfolding and ameliorating mislocalisation of CFTR mutants both in vitro and in vivo [74,75].